Previous Article | Next Article 
Journal of Virology, January 2000, p. 83-90, Vol. 74, No. 1
0022-538X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Different Regions of Hepatitis B Virus X Protein Are Required for
Enhancement of bZip-Mediated Transactivation versus
Transrepression
Sangeeta
Barnabas and
Ourania M.
Andrisani*
Department of Basic Medical Sciences, Purdue
University, West Lafayette, Indiana 47907
Received 20 May 1999/Accepted 7 September 1999
 |
ABSTRACT |
The hepatitis B virus X protein (pX) interacts directly with the
bZip transactivator CREB and the bZip repressors ICERII
and
ATF3, increasing their DNA-binding affinity in vitro and their transcriptional efficacy in vivo. However, the mechanism of
bZip-pX interaction and of the pX-mediated increase in the bZip
transcriptional efficacy remains to be understood. In this study with
deletion mutants of pX, we delineated a 67-amino-acid
region spanning residues 49 to 115 required for direct CREB, ATF3, and
ICER II
interaction in vitro and in vivo and increased bZip/CRE
binding in vitro. Transient transfections of the pX deletion mutants in
AML12 hepatocytes demonstrate that pX49-115 is as
effective as the full-length pX in enhancing the ATF3- and
ICERII
-mediated transrepression. However, this pX region
is inactive in increasing the transactivation efficacy of
CREB; additional amino acid residues present in pX49-140 are required to mediate the increased transactivation efficacy of
CREB in vivo. This requirement for different regions of pX in affecting
CREB transactivation suggests that amino acid residues 115 to
140 integrate additional events in effecting pX-mediated transactivation, such as concomitant interactions with select components of the basal transcriptional apparatus.
 |
INTRODUCTION |
The 16.5-kDa X protein, pX, encoded
by the hepatitis B virus (HBV), is expressed during viral infection
(17, 28) and is implicated in HBV-mediated
hepatocarcinogenesis by an unknown mechanism. In addition to its role
in the viral life cycle, pX exhibits several reported activities
affecting cellular transcription (35), cell growth (4,
20), and apoptotic cell death (19, 40). Importantly,
the transcriptional role of pX is implicated as a mechanism by which pX
deregulates cellular gene expression, resulting in hepatocyte
transformation (4, 41).
Although pX does not directly bind double-stranded DNA, pX activates
transcription from diverse cis-acting elements, including the AP-1 (18, 31, 36, 42), AP-2 (36), NF-
B
(23, 25, 37, 39, 43), and CRE sites (3, 26, 44).
This transcriptional promiscuity of pX is attributed to its dual
mechanism of transcriptional activation. Specifically, pX activates the
mitogenic ras-raf-MAPK (5, 11) and JNK (6)
pathways in the cytoplasm, leading to the activation of transcription
from AP-1 and NF-
B sites. pX also interacts directly with specific
components of the basal transcription apparatus, including the RPB5
subunit of RNA polymerase II (7, 24), TFIIB (15, 16,
24), and TFIIH (15, 33), and with cellular bZip
transcription factors (3, 26, 44). Importantly, distinct
regions of pX, namely, amino acids (aa) 51 to 136 and 102 to 136, are
required for the interaction of pX with RPB5 and TFIIB,
respectively (24). In addition, overexpression of RPB5 in
the presence of pX stimulates expression of pX-responsive promoters,
supporting the idea that pX transactivation occurs via direct
interaction with components of the basal transcriptional apparatus
(7). Likewise, pX rescues the transcriptional inhibitory effect of the dominant-negative TFIIB mutant C34,37S, a mutant which
maintains its interacting potential with pX (15).
Accordingly, these data favor the model that concurrent interactions
occur between pX and several components of the basal transcriptional apparatus to effect pX-mediated transactivation. However, it is not yet clear whether the direct interaction of pX with
the basal transcriptional apparatus effects a specific or general
enhancement of gene expression. In order for pX to effect increased
transcription from specific cis-acting elements, one has to
envision the recruitment by pX of the basal transcriptional apparatus
to those cis-acting elements via its interaction with
sequence-specific cellular transcription factors. The only known class
of cellular transcription factors which interacts directly with pX and
displays functional interactions in vitro and in vivo is the bZip
family of transcription factors (3, 26, 44). Our previous
studies (3, 44) demonstrated that the direct interaction of
pX with CREB/bZip family members increases transcription in a specific
manner from CRE and C/EBP
binding sites. Importantly, the
interaction of pX with the bZip transcription factor C/EBP
was shown
to synergistically activate the HBV enhancer II/pregenomic promoter
(8), supporting the idea that the interaction of pX with
bZip transcription factors is relevant for the expression of the viral genome.
Our previous studies (3, 44) have shown that pX interacts
directly with CREB via the bZip domain, increases the affinity of CREB
for either cellular or viral CRE sites by 1 order of magnitude, and
increases its transcriptional efficacy in vivo in the presence of
cyclic AMP. Likewise, pX interacts directly and increases the DNA-binding potential and transcriptional efficacy of inducible bZip
transcription factors (C/EBP
, ATF3, and ICERII
), activators or
repressors of transcription, all of which play important roles in
hepatocyte physiology (3). However, the increased
DNA-binding potential of bZip proteins (3, 44) does not
explain how pX effects their increased transcriptional efficacy.
To further understand the mechanism of bZip-pX interactions and the
mechanism mediating their increased transcriptional efficacy by
interaction with pX, we report here, first, the delineation of a pX
region required for direct CREB/bZip binding in vitro and, second, the
differential requirement of pX regions in effecting bZip-mediated
transactivation versus transrepression.
 |
MATERIALS AND METHODS |
Construction of pX deletion mutants.
GST-X79-154, GST-X49-140,
GST- X49-115, and GST-X49-90 were
constructed as protein fusions with glutathione S-transferase (GST) by PCR. The respective pX DNA fragments
were cloned into the EcoRI-HindIII sites of
the pGEX-KG plasmid (14). GST-X1-154 and
GST-X49-154 were cloned as previously described
(3). The GST-X fusion proteins were expressed in Escherichia coli and purified on glutathione-Sepharose 4B
resin (3). The protein concentration of the GST-X fusions
was estimated by densitometric analysis by using the OPTIMAS 6.1 program and employing as a standard known amounts of bovine serum
albumin (BSA), similarly analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and densitometric
analysis. In the in vitro analyses, equivalent amounts of the GST-X
deletion proteins were used.
Protein-protein interaction assays.
In vitro protein-protein
interaction assays of pX deletion mutants in fusion with GST were
carried out as previously described (3) by using
recombinant, CRE-affinity-purified CREB (47), 32P radiolabeled at the PKA (Ser133) site
(9), or in vitro-translated 35S-radiolabeled
ATF3 and ICERII
, prepared as described earlier (3).
In vitro DNA-protein binding assays.
DNA-protein binding
assays were carried out by employing the somatostatin CRE as the
radiolabeled probe (1, 3) and recombinant CREB
(9).
Transient transfections.
AML12 cells (45) were
transfected by employing the calcium phosphate coprecipitation method
or the FuGENE transfection protocol (Boehringer Mannheim) in the
presence of 10 µM forskolin and 100 µM 3-isobutyl-1-methylxanthine
(IBMX). Transfections with the luciferase reporter were performed in
triplicate in 30-mm dishes. Chloramphenicol acetyltransferase (CAT)
assays and luciferase assays were performed as previously described
(3, 44).
 |
RESULTS |
Identification of the region of pX that interacts directly with
CREB in vitro.
Earlier studies demonstrated that pX regions A, B,
and C (Fig. 1A), which are conserved to
various degrees in mammalian hepadnaviruses, are required for the
pX-mediated transactivation of the simian virus 40 (SV40) promoter
(2, 34) and Rous sarcoma virus long terminal repeat (RSV
LTR) (21). However, considering that pX mediates
transactivation of pX-responsive promoters via a dual mechanism
(11), in this study we investigated whether the same pX
region is required for the increased transcriptional efficacy of
CREB/bZip proteins by pX. Accordingly, we constructed a series of
deletion mutants of pX (Fig. 1A) by PCR-based cloning of the respective
fragments into the pGEX-KG vector (14). The rationale for
constructing these mutants is that pX49-154 lacks the first 48 aa of pX known to repress pX-mediated transactivation (29) and pX79-154 starts at an internal Met
residue (22). pX49-140 contains regions A, B,
and C (Fig. 1A) required for pX-mediated transactivation of the SV40
promoter (2, 34) and RSV LTR (21).
pX49-115 contains regions A and B, and pX49-90 contains only region A (Fig. 1A).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Diagram of constructed pX deletion mutants. pX
regions A, B, and C are conserved to various degrees in hepadnaviruses
and are essential for transactivation. C61 and
C69 are conserved cysteines. The polymerase II, RPB5
subunit, TFIIH, and TFIIB interacting regions are indicated. (B)
Coomassie blue-stained SDS gel (14%) of purified (4),
recombinant GST-X and the indicated pX deletions. , GST-X fusion
protein; *, endogenously cleaved GST portion. (C) Western blot of
recombinant wt pX, pX49-154, pX79-154,
pX49-140, pX49-115, and pX49-90
(GST fusions) detected with a polyclonal pX-specific antibody. ,
GST-X fusion protein. Protein bands smaller than the GST-X fusion
proteins are degradation products.
|
|
These pX deletion mutants (Fig.
1A) were expressed as GST fusion
proteins, purified (Fig.
1B) as previously described (
3),
and analyzed by Western blotting (Fig.
1C). All pX mutants express
soluble GST-X fusion protein. To determine the potential of these
pX
deletion mutants to interact directly with CREB, we carried
out in
vitro protein-protein interaction assays by using the GST-X
fusion
proteins and CREB as the interacting protein (
3).
Recombinant
CREB was purified by CRE-affinity chromatography
(
47) and radiolabeled
with protein kinase A at
Ser
133 as previously described (
9).
In order to ensure that the protein-protein interaction assays were
performed at concentrations of CREB corresponding to the
linear range
for pX binding, we quantitated the relative
Kd
of
CREB-pX interactions.
Kd quantitations were
performed by employing
the previously established in vitro
protein-protein interaction
assay, thereby detecting specific
interaction between CREB and
pX (
3). Increasing amounts of
CRE affinity-purified (
47),
32P-radiolabeled
CREB (
9), ranging in concentration from 0.2
to 62.5 nM, was
incubated with a constant amount of GST-X
1-154.
After
binding and electrophoretic analysis, the bound fraction
was
quantitated by scintillation counting of the SDS-PAGE-excised
bands.
Control in these assays included the binding of
32P-CREB to
an equivalent amount of GST-bound resin. We estimated
the relative
Kd to be in the range of 1.8 × 10
8 M (Fig.
2).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Kd determination of CREB-pX
interaction. GST-X1-154 resin ( ) (5 µg) was incubated
with increasing amounts of 32P-CREB (0.2 to 62.5 nM) for
3 h at 4°C in buffer containing 25 mM HEPES (pH 7.5), 100 mM
KCl, 0.1% Triton X-100, 5 mM dithiothreitol, 5 mM phenylmethylsulfonyl
fluoride, and 50 µg of BSA per ml. The beads were washed six times
and eluted by boiling in SDS-PAGE loading buffer. Analysis was done on
SDS-12% PAGE gels. Equivalent amounts of GST-bound resin ( ) or
equal amounts of glutathione beads ( ) were used as the control.
Bound CREB was plotted against the total concentration of CREB. The
Kd value was calculated as the concentration of
CREB at which half-maximal binding to GST-X was observed. The
experiment was repeated three times and shows a
Kd value of approximately 1.8 × 10 8 M. A representative experiment from three independent
experiments is shown above.
|
|
Employing
32P-CREB in the concentration corresponding to
the linear range for pX binding, we assessed the potential of the pX
deletion mutants to interact with CREB (Fig.
3A and B). Equivalent
amounts of protein for each GST-X deletion mutant were used in
these in
vitro assays and assessed by densitometric analysis,
using as a
standard known amounts of BSA. GST-X
49-154,
GST-X
49-140,
and GST-X
49-115 display binding
comparable to wild-type
(wt) pX. GST-X
79-154 and
GST-X
49-90, in comparison
to full-length pX, display only
30 and 20% binding to CREB, respectively
(Fig.
3A and B). From the
analysis of these pX deletion mutants,
we conclude that the smallest
region of pX required for direct
CREB binding is the 67-aa region
spanning residues 49 to 115.
This region is rich in Cys residues and
contains regions A and
B, which are essential for pX-mediated
transactivation of the
SV40 early promoter (
2,
34) and the
RSV LTR (
21).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Activity of pX deletions in vitro. (A) Protein-protein
interaction assay with equivalent amounts of GST-X deletion mutants (3 µg) incubated with 32P-CREB (5 to 10 ng) for 3 h at
4°C in buffer containing 25 mM HEPES (pH 7.5), 100 mM KCl, 0.1%
Triton X-100, 5 mM dithiothreitol, 5 mM phenylmethylsulfonyl fluoride,
and 50 µg of BSA per ml. The beads were washed six times and eluted
by boiling in SDS-PAGE loading buffer. Analysis was done by SDS-PAGE on
12% gels. A total of 12 to 15 µg of GST bound to resin was used as a
control. (B) Quantitation of relative CREB binding to each GST-X
deletion mutant compared to wt pX carried out by scintillation counting
of the gel excised bands. Nonspecific binding of CREB to the GST-resin
control is subtracted from all of the plotted values. The data shown
are from four independent experiments. (C) DNA-protein binding assays of recombinant CREB in the
presence of pX mutants were carried out as described previously
(3) with 10 ng of recombinant CREB and 10,000 cpm of
radiolabeled CRE, with an equivalent amount of the following: + lanes,
GST-X49-140, GST-X49-115, and
GST-X49-90; lanes, recombinant GST protein, as
indicated. Lanes containing GST-X49-90 were exposed for 2 days at 80°C during autoradiography, as opposed to 18 h of
exposure for the other lanes.
|
|
Identification of the minimal functional region of pX that enhances
the DNA-binding potential of CREB in vitro.
To determine the
functional significance of the interaction of pX49-140 and
pX49-115 with CREB, we tested the potential of these pX
deletion mutants to enhance the CRE-binding potential of CREB in vitro.
Gel retardation assays were performed by employing radiolabeled CRE as
the probe (3) and recombinant CREB (9) in the
presence or absence of the pX deletion mutants pX49-140,
pX49-115, and pX49-90. Addition of equivalent
amounts of either pX49-140 or pX49-115 enhanced the CRE-binding potential of CREB (Fig. 3C). By contrast, addition of equivalent amounts of pX49-90, which displays 80% reduced binding to CREB in vitro (Fig. 3B), failed to enhance the
CRE-binding potential of CREB (Fig. 3C). Accordingly, we have delineated a minimal functional region of pX containing 67 aa residues,
pX49-115, that is required for direct CREB interaction and
enhanced CREB/CRE binding in vitro.
In vivo activity of the pX mutants in AML12 hepatocytes.
To
confirm the in vitro results by in vivo analyses, we performed two
types of assays in AML12 hepatocytes. First, we examined whether
pX49-140 and pX49-115 interact directly with CREB in vivo by employing the mammalian two-hybrid assay. Second, we
examined by transient-transfection assays in AML12 cells whether these
pX deletion mutants are active in enhancing the transcriptional efficacy of CREB in vivo.
pX
49-140 and pX
49-115 were cloned in frame
with the DNA-binding domain of Gal4
1-147 in the RSV
LTR-driven
expressor vector (
3). The interacting CREB
protein is in fusion
with the activation domain of VP16 as described
earlier (
3).
Transient transfections in AML12 hepatocytes
were carried out
by using the Gal4
UAS-luciferase reporter
in the presence of CREB-VP16
encoding plasmid, as a function of the
RSV-X-Gal4 expression vectors
(Fig.
4A).
In agreement with the in vitro results (Fig.
3), the
mammalian
two-hybrid assays demonstrate that both pX
49-140 and
pX
49-115, like wt pX, interact directly with CREB in
vivo.
However, it is important to note that this assay does not
allow
quantitative comparison of these interactions among the
three pX
constructs tested.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Activity of pX deletions in vivo. (A) Mammalian
two-hybrid assay of pX deletion mutants in AML12 cells. A total of 500 ng of Gal4UAS-luciferase reporter was cotransfected by the
FuGENE transfection protocol, with 700 ng each of RSV-CREB-VP16 and
RSV-X-Gal4 expression vectors per 30-mm culture dish, performed in
triplicate. Cells were harvested 18 h after transfection, and
luciferase activity was quantitated and expressed per microgram of
protein extract as previously described (3). Results are
from three independent experiments. (B) Transient transfection of HBV
pX mutants in AML12 cells. A total of 3 to 5 µg of
CRE3-CAT reporter plasmid was cotransfected with pCMV-X-NLS
(20 ng), pCMV-X49-140 (100 ng), and
pCMV-X49-115 (50 ng) expressor plasmid. Control
transfections contained equivalent amounts of pCMV-empty vector. The
optimal amounts of pCMV-X expression vectors shown (wt and mutants)
were established by titration analyses. Transfected cells were treated
with 10 µM forskolin and 100 µM IBMX and harvested at 24 h.
CAT assays were performed as described earlier (3).
Relative CRE3-CAT induction values per microgram of protein
extract were quantitated from three independent experiments.
|
|
To examine the potential of these CREB interacting regions of pX to
increase the transcriptional efficacy of CREB in vivo,
mammalian
expression vectors encoding pX
49-140 and
pX
49-115 were cotransfected at low density with the
CRE
3-CAT reporter in the AML12 hepatocyte cell line (Fig.
4B). In
agreement with similar observations by others (
10,
35,
38),
we observe that wt pX is a weak transactivator, displaying a
twofold
induction in CREB/CRE-mediated transcription in the AML12
hepatocyte
cell line. Like wt pX, pX
49-140 induces the
transactivation
of endogenous CREB by approximately two- to threefold.
By contrast,
pX
49-115 shows a minimal 1.4-fold induction
of the CRE
3-CAT reporter (Fig.
4B). These results
demonstrate that pX
49-140 retains its ability to
transactivate CRE-mediated transcription
in a manner similar to that of
wt pX. However, in contrast to
pX
49-140,
pX
49-115 which interacts directly with CREB
both in vitro
(Fig.
3) and in vivo (Fig.
4B) and enhances its
CRE-binding potential
in DNA-protein binding assays (Fig.
3C)
displays minimal
transactivation in vivo. These results suggest
that the increased
transcriptional efficacy of CREB effected by
pX requires other
pX-dependent events in addition to the increased
CRE binding of
CREB.
Interaction of pX49-140 and pX49-115 with
bZip repressors ATF3 and ICERII
.
Since pX displays promiscuity
in its interaction with bZip proteins (3), we examined
whether these characterized pX deletion mutants display the same
requirements in interacting with various bZip proteins. We selected the
bZip proteins ATF3, ICERII
, and NF-IL6, which were shown previously
to undergo functional interactions with pX (3). In vitro
protein-protein interaction assays were carried out by using the GST
fusion proteins of wt pX, pX49-140, pX49-115,
and pX49-90 with in vitro-translated ICERII
, ATF3, and
the bZip domain of NF-IL6 (data not shown). We observed (Fig.
5) that ATF3 interacts with both
pX49-140 and pX49-115 in a way similar
to wt pX. ICERII
also interacts with both
pX49-140 and pX49-115 deletions,
although in comparison to wt pX it displays reduced direct binding to
these regions. Like CREB, neither ATF3 nor ICERII
displays
appreciable direct binding to pX49-90 (Fig. 5). Therefore,
all of the bZip proteins tested interact with the same minimal region
of pX, spanning aa 49 to 115, which is also required for interaction
with CREB in vitro (Fig. 3) and in vivo (Fig. 4A). These results
support the idea that a common mechanism exists for the interaction of
bZip transcription factors with viral pX.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Interaction of pX deletions with ATF3 and ICERII . (A)
Protein-protein interaction assays of GST-X, GST-X49-140,
GST-X49-115, and GST-X49-90 with in
vitro-translated, [35S]methionine-radiolabeled ATF3 (3 µl) and ICERII (7 µl) as indicated. Experimental conditions were
as described in Fig. 3A. (B) Quantitation of relative ATF3 and
ICERII binding to each GST-X deletion mutant compared to wt pX as
determined by scintillation counting of the gel-excised bands.
Nonspecific binding of ATF3 and ICERII to the GST-bound resin is
subtracted from all of the plotted values. The data shown are from
three independent experiments.
|
|
In vivo activity of the pX mutants in mediating repression by ATF3
and ICERII
.
To assess the activity of deletions
pX49-115 and pX49-140 in mediating enhanced
transrepression by ATF3 and ICERII
, expression vectors encoding each
of the pX deletion constructs were cotransfected with ATF3 or ICERII
in AML12 cells by employing the CRE-driven reporters CRE-luciferase
(Fig. 6A) and CRE3-CAT (Fig.
6B), respectively. Earlier studies demonstrated that ATF3 and ICERII
repress CRE3-CAT expression, and pX coexpression further
increases their transrepression efficacy (3). The results
shown in Fig. 6 demonstrate that, like wt pX, both
pX49-140 and pX49-115 further promote the
repression efficacy of ATF3 and ICERII
. Therefore, while the
pX-mediated enhancement of CREB/CRE transcription requires the pX
region spanning aa 49 to 140 (Fig. 4B), the pX-mediated increase
in the repression efficacy of ATF3 and ICERII
occurs as
efficiently with pX49-115 (Fig. 6). Importantly, the functional activity of pX49-115 in promoting ATF3- and
ICERII
-mediated repression excludes the possibility that this
deletion mutant is unstable in vivo.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Transient transfection of HBV pX mutants in AML12 cells
in the presence of bZip repressors ATF3 and ICERII . (A) A total of
600 ng of CRE-luciferase reporter plasmid was cotransfected by the
FuGENE protocol (Boehringer Mannheim) with 100 ng of pCMV-X-NLS,
pCMV-X49-140, and pCMV-X49-115 expressor
plasmid in the presence of 50 ng of ATF3 expression vector. (B)
CRE3-CAT reporter plasmid (5 µg) cotransfected by the
calcium phosphate protocol (BRL) with pCMV-X-NLS (20 ng),
pCMV-X49-140 (50 ng), and pCMV-X49-115 (50 ng) expressor plasmid in the presence of 0.5 µg of ICERII . Optimal
amounts of the indicated expression vectors transfected in AML12 cells
were determined by titration analyses. Relative CRE3-CAT
activities per microgram of protein extract were quantitated from three
independent experiments.
|
|
Since pX
49-115 is the minimal, functional region required
for CREB/bZip interaction in vitro, the observed increased
repression
efficacy of ATF3 and ICERII

effected by pX
49-115 in
vivo (Fig.
6) is a direct demonstration of the functional importance
of
the interaction of pX with bZip transcription factors. Specifically,
our results identify the increased DNA-binding potential of bZip
proteins effected by pX as the initial pX-dependent event, leading
to
increased transactivation or transrepression by bZip transcription
factors.
 |
DISCUSSION |
Our earlier studies have demonstrated that the interaction of pX
with bZip transcription factors CREB, ICERII
, ATF3, and NF-IL6
increases their DNA-binding affinity in vitro and their transcriptional
efficacy in vivo (3, 44). In the present study we have
employed the CREB-pX model system to examine the mechanism by which pX
increases the transcriptional efficacy of bZip transcription factors.
Our approach was to define a minimal, functional region of pX required
for CREB interaction and activity. The rationale for undertaking these
studies was that the definition of a minimal region of pX will provide
convincing evidence to demonstrate the specificity of CREB (bZip)-pX
interactions and will also provide a useful tool for biophysical
analyses of pX and the bZip-pX complex.
We report the delineation of a 67-aa region of pX, spanning aa 49 to
115, as the minimal region required for direct CREB binding (Fig. 3 and
4A) and for the enhancement of the CRE-binding potential of CREB (Fig.
3C). Interestingly, although this minimal region of pX enhances the
CRE-binding potential of CREB in vitro, it only minimally increases the
transcriptional efficacy of CREB in vivo (Fig. 4B). By contrast,
pX49-140 enhances both the CRE-binding potential of CREB
(Fig. 3C) and its transcriptional efficacy in vivo (Fig. 4B). The
transcriptionally active deletion pX49-140, tested by
CREB/CRE-driven transcriptional induction, contains pX regions A, B,
and C, all of which are required for transactivation of both the SV40
early promoter (34) and the RSV LTR (21).
Importantly, this pX region has been shown to contain binding sites for
both the RPB5 subunit of RNA polymerase II and TFIIB, mapped at amino
acid residues 51 to 136 and 102 to 136, respectively (24).
By contrast pX49-115, which results in a minimal increase
in the transcriptional efficacy of CREB (Fig. 4B), lacks region C; this
region contains a portion of the binding sites for RPB5 and TFIIB
(25) and nine conserved amino acids (132 to 140), which were
shown to be required for pX-mediated transactivation (2,
34).
Therefore, it is interesting to speculate that concomitant interactions
of pX with the bZip transcription factors and with one or more
components of the basal transcriptional apparatus account for the
pX-mediated enhancement of CRE transcription in vivo (Fig.
7). Since both pX49-140 and
pX49-115 are functional in vitro (Fig. 3C), whereas
only pX49-140 is functional in vivo (Fig. 4B), these data
suggest that the interaction of pX with CREB may bridge specific
components of the transcriptional apparatus to effect the observed
increased transcriptional efficacy of CREB.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 7.
Model depicting concomitant interactions of pX with bZip
transcription factors and the basal transcriptional apparatus. (A and
B) pX-mediated CREB transactivation effected by pX49-140
(containing regions A, B, and C) and pX49-115 (containing
regions A and B), respectively. (C and D) pX-mediated ICERII
transrepression effected by pX49-140 and
pX49-115, respectively.
|
|
Based on in vitro transcription analyses and subcellular fractionation
studies (30), it has been demonstrated that activated CREB
interacts with the basal transcriptional apparatus at two distinct
levels: (i) phospho(Ser133)-CREB recruits RNA polymerase II
via interaction with CBP and (ii) the Q2 region of CREB
associates with TFIID via interaction with hTAFII130.
Accordingly, we propose that pX49-140, containing the
conserved regions A, B, and C, tethers or stabilizes the
transcriptional initiation complex via interaction with TFIIB or the
RPB5 subunit of RNA polymerase II, as shown in Fig. 7A. According
to our model, deletion of pX region C (Fig. 7B) only minimally promotes
the interaction with the basal transcriptional apparatus, resulting in
minimal induction of CREB-driven transcription. The significance of our
observations and our proposed model is that CREB and the various bZip
proteins (3) represent nonartificial, physiological cellular
targets of pX (3, 26, 44). Furthermore, since bZip
cis-acting elements are present within the HBV enhancers I
and II (8, 12, 26), our model is relevant not only for
cellular gene expression but also for the expression of the viral
genome. Further studies are required to demonstrate directly the role
of pX in bridging specific components of the basal transcriptional
apparatus to CREB/bZip transcription factors.
Regarding the mechanism of the increased repression efficacy displayed
by bZip repressors in the presence of pX (3), our results
(Fig. 6) demonstrate that the minimal pX49-115 is as
effective as the wt pX in increasing the repression efficacy of ATF3
and ICERII
in vivo. Since pX49-115 interacts directly with bZip proteins in vitro (Fig. 3 and 5) and in vivo (Fig. 4A) and
also increases the CRE-binding potential of CREB in vitro (Fig. 3C), we
interpret these observations as direct evidence in support of the
importance of the increased DNA-binding potential of bZip proteins by
pX in mediating enhanced bZip-driven transactivation or
transrepression. Moreover, these results lend further support to the
importance of the interaction of pX with the basal transcriptional apparatus (7, 15, 16, 24, 33). ICERII
represses
CRE-mediated transcription due to lack of an activation domain
(27). Accordingly, ICERII
is an example of a
transcriptional repressor not engaging the basal transcriptional
apparatus. The increased DNA-binding potential effected by
pX49-115 is sufficient to mediate repression by ICERII
(Fig. 7C and D). We conclude that while pX-dependent coactivation is
crucial in mediating CREB/CRE-driven transactivation, the interaction
of pX with the basal transcriptional apparatus is not required for
ICERII
- or ATF3-driven transcriptional repression (Fig. 6).
Since the minimal, functional pX region required for CREB interaction
is also required for direct interaction with other bZip proteins (ATF3,
ICERII
, and NF-IL6), this observation (Fig. 5) supports the idea
that a common mechanism exists for the interaction of pX with bZip
family members. Accordingly, this minimal region of pX is a powerful
tool for biophysical studies, in order to determine the structural
features of the CREB (bZip) interacting region of pX and its
interaction with CREB/bZip family members. Importantly, no structural
information is yet available for pX. Both pX mutants, spanning amino
acid residues 49 to 140 and 49 to 115, express 1 to 2 mg of
soluble protein per liter of bacterial culture (data not shown).
Thus, these pX deletion mutants are amenable to biophysical analyses.
The information derived from the biophysical studies should provide an
important contribution toward understanding pX and, by examining
naturally occurring pX variants, will provide a new approach to address
the clinical relevance of CREB (bZip)-pX interactions. Very little is
known of the sequence variations of pX, mainly because the pX gene
overlaps the viral polymerase gene (46) and the precore gene
(32) and carries several signals critical to the replicative
viral lifecycle (13). It will be interesting to examine
these naturally occurring sequence variations from the perspective of
CREB-bZip interactions, employing our well-defined in vitro and in vivo
functional assays (3, 41, 44).
 |
ACKNOWLEDGMENTS |
We thank R. L. Hullinger and Chi Tarn for critical reviews
of the manuscript and for help with illustrations.
This work was supported by National Institute of Health grant DK44533
and American Cancer Society grant CN82450 to O.M.A.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Basic Medical Sciences, Purdue University, 1246 Lynn Hall, West
Lafayette, IN 47907-1246. Phone: (765) 494-8131. Fax: (765) 494-0781. E-mail: oma{at}vet.purdue.edu.
 |
REFERENCES |
| 1.
|
Andrisani, O. M.,
D. A. Pot,
Z. Zhu, and J. E. Dixon.
1988.
Three sequence-specific DNA-protein complexes are formed with the same promoter element essential for expression of the rat somatostatin gene.
Mol. Cell. Biol.
8:1947-1956[Abstract/Free Full Text].
|
| 2.
|
Arii, M.,
K. Takada, and K. Koike.
1992.
Identification of three essential regions of hepatitis B virus X protein for trans-activation function.
Oncogene
7:397-403[Medline].
|
| 3.
|
Barnabas, S.,
T. Hai, and O. M. Andrisani.
1997.
The hepatitis B virus X protein enhances the DNA-binding potential and transcription efficacy of bZip transcription factors.
J. Biol. Chem.
272:20684-20690[Abstract/Free Full Text].
|
| 4.
|
Benn, J., and R. J. Schneider.
1995.
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.
Proc. Natl. Acad. Sci. USA
92:11215-11219[Abstract/Free Full Text].
|
| 5.
|
Benn, J., and R. J. Schneider.
1994.
Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade.
Proc. Natl. Acad. Sci. USA
91:10350-10354[Abstract/Free Full Text].
|
| 6.
|
Benn, J.,
F. Su,
M. Doria, and R. J. Schneider.
1996.
Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases.
J. Virol.
70:4978-4985[Abstract/Free Full Text].
|
| 7.
|
Cheong, J. H.,
M. Yi,
Y. Lin, and S. Murakami.
1995.
Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation.
EMBO J.
14:143-150[Medline].
|
| 8.
|
Choi, B. H.,
G. T. Park, and H. M. Rho.
1999.
Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein synergistically activates the hepatitis B viral enhancer II/pregenomic promoter.
J. Biol. Chem.
274:2858-2865[Abstract/Free Full Text].
|
| 9.
|
Colbran, J. L.,
P. J. Roach,
C. J. Fiol,
J. E. Dixon,
O. M. Andrisani, and J. D. Corbin.
1992.
cAMP-dependent protein kinase, but not the cGMP-dependent enzyme, rapidly phosphorylates -CREB, and a synthetic -CREB peptide.
Biochem. Cell Biol.
70:1277-1282[Medline].
|
| 10.
|
Colgrove, R.,
G. Simon, and D. Ganem.
1989.
Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication.
J. Virol.
63:4019-4026[Abstract/Free Full Text].
|
| 11.
|
Doria, M.,
N. Klein,
R. Lucito, and R. J. Schneider.
1995.
The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors.
EMBO J.
14:4747-4757[Medline].
|
| 12.
|
Faktor, O.,
S. Budlovsky,
R. Ben-Levy, and Y. Shaul.
1990.
A single element within the hepatitis B virus enhancer binds multiple proteins and responds to multiple stimuli.
J. Virol.
64:1861-1863[Abstract/Free Full Text].
|
| 13.
|
Ganem, D.,
J. R. Pollack, and J. Tavis.
1994.
Hepatitis B virus reverse transcriptase and its many roles in hepadnaviral genomic replication.
Infect. Agents Dis.
3:85-93[Medline].
|
| 14.
|
Guan, K., and J. E. Dixon.
1991.
Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase.
Anal. Biochem.
192:262-267[CrossRef][Medline].
|
| 15.
|
Haviv, I.,
M. Shamay,
G. Doitsch, and Y. Shaul.
1998.
Hepatitis B virus pX targets TFIIB in transcription coactivation.
Mol. Cell. Biol.
18:1562-1569[Abstract/Free Full Text].
|
| 16.
|
Haviv, I.,
D. Vaizel, and Y. Shaul.
1996.
pX, the HBV-encoded transactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner.
EMBO J.
15:3413-3420[Medline].
|
| 17.
|
Kay, A.,
E. Mandart,
C. Trepo, and F. Galibert.
1985.
The HBV HBx gene expressed in E. coli is recognized by sera from hepatitis patients.
EMBO J.
4:1287-1292[Medline].
|
| 18.
|
Kekule, A. S.,
U. Lauer,
L. Weiss,
B. Luber, and P. H. Hofschneider.
1993.
Hepatitis B virus transactivator HBx uses a tumor promoter signalling pathway.
Nature
361:742-745[CrossRef][Medline].
|
| 19.
|
Kim, H.,
H. Lee, and Y. Yun.
1998.
X-gene product of hepatitis B virus induces apoptosis in liver cells.
J. Biol. Chem.
273:382-385.
|
| 20.
|
Koike, K.,
K. Moriya,
H. Yotsuyanagi,
S. Iino, and K. Kurokawa.
1994.
Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts.
J. Clin. Investig.
94:44-49.
|
| 21.
|
Kumar, V.,
N. Jayasuryan, and R. Kumar.
1996.
A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function.
Proc. Natl. Acad. Sci. USA
93:5647-5652[Abstract/Free Full Text].
|
| 22.
|
Kwee, L.,
R. Lucito,
B. Aufiero, and R. J. Schneider.
1992.
Alternate translation initiation on hepatitis B virus X mRNA produces multiple polypeptides that differentially trans-activate class II and III promoters.
J. Virol.
66:4382-4389[Abstract/Free Full Text].
|
| 23.
|
Levrero, M.,
C. Balsano,
G. Natoli,
M. L. Avantaggiati, and E. Elfassi.
1990.
Hepatitis B virus X protein transactivates the long terminal repeats of human virus types 1 and 2.
J. Virol.
64:3082-3086[Abstract/Free Full Text].
|
| 24.
|
Lin, Y.,
T. Nomura,
J. Cheong,
D. Dorjsuren,
K. Iida, and S. Murakami.
1997.
Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.
J. Biol. Chem.
272:7132-7139[Abstract/Free Full Text].
|
| 25.
|
Lucito, R., and R. J. Schneider.
1992.
Hepatitis B virus X protein activates transcription factor NF- B without a requirement for protein kinase C.
J. Virol.
66:983-991[Abstract/Free Full Text].
|
| 26.
|
Maguire, H. F.,
J. P. Hoeffler, and A. Siddiqui.
1991.
HBV X protein alters the DNA binding specificity of CREB and ATF2 by protein-protein interactions.
Science
252:842-844[Abstract/Free Full Text].
|
| 27.
|
Molina, C. A.,
N. S. Foulkes,
E. Lalli, and P. Sassone-Corsi.
1993.
Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of an early response repressor.
Cell
75:875-886[CrossRef][Medline].
|
| 28.
|
Moriarity, A. M.,
H. Alexander,
R. A. Lerner, and G. B. Thornton.
1985.
Antibodies to peptide detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma.
Science
227:429-433[Abstract/Free Full Text].
|
| 29.
|
Murakami, S.,
J. H. Cheong, and S. Kaneko.
1994.
Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein.
J. Biol. Chem.
269:15118-15123[Abstract/Free Full Text].
|
| 30.
|
Nakajima, T.,
C. Uchida,
S. Anderson,
J. Parvin, and M. Montminy.
1997.
Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors.
Genes Dev.
11:738-747[Abstract/Free Full Text].
|
| 31.
|
Natoli, G.,
M. L. Avantaggiati,
P. Chirillo,
A. Costanzo,
M. Artini,
C. Balsano, and M. Levrero.
1994.
Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX.
Mol. Cell. Biol.
14:989-998[Abstract/Free Full Text].
|
| 32.
|
Okamoto, H.,
F. Tsuda,
Y. Akahane,
Y. Sugai,
M. Yoshiba,
K. Moriyama,
T. Tanaka,
Y. Miyakawa, and M. Mayumi.
1994.
Hepatitis B virus with mutations in the core promoter for an e-antigen phenotype in carriers with antibody to e antigen.
J. Virol.
68:8102-8110[Abstract/Free Full Text].
|
| 33.
|
Qadri, I.,
J. W. Conaway,
R. C. Conaway,
J. Schaack, and A. Siddiqui.
1996.
Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH.
Proc. Natl. Acad. Sci. USA
93:10578-10583[Abstract/Free Full Text].
|
| 34.
|
Renner, M.,
A. Haniel,
E. Burgelt,
P. H. Hofschneider, and W. Koch.
1995.
Transactivating function and expression of the X gene of the hepatitis B virus.
J. Hepatol.
23:53-65[CrossRef][Medline].
|
| 35.
|
Rosner, M. T.
1992.
Hepatitis B virus X-gene product: a promiscuous transcriptional activator.
J. Med. Virol.
36:101-117[CrossRef][Medline].
|
| 36.
|
Seto, E.,
P. J. Mitchell, and T. S. B. Yen.
1990.
Transactivation of the hepatitis B virus X protein depends on AP-2 and other transcription factors.
Nature
344:72-74[Medline].
|
| 37.
|
Seto, E.,
T. Yen,
B. Peterlin, and J. Ou.
1988.
Transactivation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein.
Proc. Natl. Acad. Sci. USA
85:8286-8290[Abstract/Free Full Text].
|
| 38.
|
Seto, E.,
D. Zhou,
M. Peterlin, and B. Yen.
1989.
Transactivation by the hepatitis B virus X protein shows cell-type specificity.
Virology
173:764-766[CrossRef][Medline].
|
| 39.
|
Siddiqui, A.,
R. Gaynor,
A. Srinivasan,
J. Mapoles, and R. W. Farr.
1989.
Transactivation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein.
Virology
16:479-484.
|
| 40.
|
Su, F., and R. J. Schneider.
1997.
Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor .
Proc. Natl. Acad. Sci. USA
94:8744-8749[Abstract/Free Full Text].
|
| 41.
|
Tarn, C.,
M. Bilodeau,
R. Hullinger, and O. M. Andrisani.
1999.
Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines.
J. Biol. Chem.
274:2327-2336[Abstract/Free Full Text].
|
| 42.
|
Twu, J. S.,
M. Y. Lai,
D. S. Chen, and W. S. Robinson.
1993.
Activation of protooncogene c-jun by the X protein of the hepatitis B virus.
Virology
192:346-350[CrossRef][Medline].
|
| 43.
|
Twu, J. S.,
J. Wu, and W. S. Robinson.
1990.
Transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat by hepatitis B virus X-protein requires de novo protein synthesis.
Virology
177:406-410[CrossRef][Medline].
|
| 44.
|
Williams, J. S., and O. M. Andrisani.
1995.
The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB.
Proc. Natl. Acad. Sci. USA
92:3819-3823[Abstract/Free Full Text].
|
| 45.
|
Wu, J. C.,
G. Merlino, and N. Fausto.
1994.
Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor .
Proc. Natl. Acad. Sci. USA
91:674-678[Abstract/Free Full Text].
|
| 46.
|
Yuh, C. H.,
Y. L. Chang, and L. P. Ting.
1992.
Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus.
J. Virol.
66:4073-4084[Abstract/Free Full Text].
|
| 47.
|
Zhu, Z.,
O. M. Andrisani,
D. A. Pot, and J. E. Dixon.
1989.
Purification and characterization of a 43-kDa transcription factor required for rat somatostatin gene expression.
J. Biol. Chem.
264:6550-6556[Abstract/Free Full Text].
|
Journal of Virology, January 2000, p. 83-90, Vol. 74, No. 1
0022-538X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Whitmore, M. M., Iparraguirre, A., Kubelka, L., Weninger, W., Hai, T., Williams, B. R. G.
(2007). Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-3. J. Immunol.
179: 3622-3630
[Abstract]
[Full Text]
-
Cougot, D., Wu, Y., Cairo, S., Caramel, J., Renard, C.-A., Levy, L., Buendia, M. A., Neuveut, C.
(2007). The Hepatitis B Virus X Protein Functionally Interacts with CREB-binding Protein/p300 in the Regulation of CREB-mediated Transcription. J. Biol. Chem.
282: 4277-4287
[Abstract]
[Full Text]
-
Li, H., Chi, C.-Y., Lee, S., Andrisani, O. M.
(2006). The Mitogenic Function of Hepatitis B Virus X Protein Resides within Amino Acids 51 to 140 and Is Modulated by N- and C-Terminal Regulatory Regions. J. Virol.
80: 10554-10564
[Abstract]
[Full Text]
-
Tarn, C., Zou, L., Hullinger, R. L., Andrisani, O. M.
(2002). Hepatitis B Virus X Protein Activates the p38 Mitogen-Activated Protein Kinase Pathway in Dedifferentiated Hepatocytes. J. Virol.
76: 9763-9772
[Abstract]
[Full Text]
-
Li, J., Xu, Z., Zheng, Y., Johnson, D. L., Ou, J.-h.
(2002). Regulation of Hepatocyte Nuclear Factor 1 Activity by Wild-Type and Mutant Hepatitis B Virus X Proteins. J. Virol.
76: 5875-5881
[Abstract]
[Full Text]
-
Xu, Z., Yen, T. S. B., Wu, L., Madden, C. R., Tan, W., Slagle, B. L., Ou, J.-h.
(2002). Enhancement of Hepatitis B Virus Replication by Its X Protein in Transgenic Mice. J. Virol.
76: 2579-2584
[Abstract]
[Full Text]
-
Lee, S., Tarn, C., Wang, W.-H., Chen, S., Hullinger, R. L., Andrisani, O. M.
(2002). Hepatitis B Virus X Protein Differentially Regulates Cell Cycle Progression in X-transforming Versus Nontransforming Hepatocyte (AML12) Cell Lines. J. Biol. Chem.
277: 8730-8740
[Abstract]
[Full Text]
-
Tarn, C., Lee, S., Hu, Y., Ashendel, C., Andrisani, O. M.
(2001). Hepatitis B Virus X Protein Differentially Activates RAS-RAF-MAPK and JNK Pathways in X-transforming Versus Non-transforming AML12 Hepatocytes. J. Biol. Chem.
276: 34671-34680
[Abstract]
[Full Text]